Drug Approval | July 02, 2022
Ascentage Pharma gets IND clearance by the US FDA for novel EED Inhibitor APG-5918
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
An interim analysis of this data shows no significant safety issues and a 91% seroconversion rate at Day 56.
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
Low-dose atropine has emerged as an effective approach to slow the progression of myopia in children
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
The two-year agreement will grant Lonza access to IBF's prominent network and allow IBF to benefit from Lonza's manufacturing expertise and knowledge in its due diligence review of potential targets
Lonza to expand inhalation services by adding capabilities at its Tampa (US) site as part of its continued focus on providing bioavailability enhancement series for global customers
As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications
The study will evaluate the effectiveness of Nantheia ATL5, an investigational drug using cannabidiol in ANANDA’s proprietary delivery technology
Subscribe To Our Newsletter & Stay Updated
